|
|
|
|
|
|
|
01.12.25 - 07:03
|
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025 (GlobeNewswire EN)
|
|
|
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025...
|
|
|
|
|
|
|
|
|
|
|
|
|
26.09.25 - 07:03
|
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 (GlobeNewswire EN)
|
|
|
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025....
|
|
|
|
|
|
|
|
|
|
|
19.06.25 - 08:24
|
Addex sieht sich nach Q1 auf gutem Weg (Moneycab)
|
|
|
Das Biotechunternehmen Addex ist gut in das neue Geschäftsjahr 2025 gestartet. Für den weiteren Geschäftsverlauf stehen dem Genfer Unternehmen liquide Mittel in Höhe von 2,8 Millionen Franken zur Verfügung....
|
|
|
|
|
|
|
18.06.25 - 07:03
|
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 (GlobeNewswire EN)
|
|
|
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day....
|
|
|
|
|
05.06.25 - 07:03
|
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference (GlobeNewswire EN)
|
|
|
Geneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that preclinical data from its gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) cough program will be presented at the 10th American Cough Conference (June 6-7) in Dulles, VA....
|
|
|
03.06.25 - 07:03
|
Addex Convenes Annual General Meeting 2025 (GlobeNewswire EN)
|
|
|
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am)....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
